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ABSTRACT
Background: The risk of infection with human papillomavirus (HPV)
increases with age. Answering the question of which age groups are
appropriate to target for catch-up vaccination with the newly licensed
quadrivalent HPV vaccine (types 6/11/16/18) will be important for devel-
oping vaccine policy recommendations.
Objectives: To assess the value of varying female HPV vaccination
strategies by speciﬁc age groups of a catch-up program in the United
States.
Methods: The authors used previously published mathematical popula-
tion dynamic model and cost-utility analysis to evaluate the public health
impact and cost-effectiveness of alternative quadrivalent HPV (6/11/16/
18) vaccination strategies. The model simulates heterosexual transmission
of HPV infection and occurrence of cervical intraepithelial neoplasia
(CIN), cervical cancer, and external genital warts in an age-structured
population stratiﬁed by sex and sexual activity groups. The cost-utility
analysis estimates the cost of vaccination, screening, diagnosis, and treat-
ment of HPV diseases, and quality-adjusted survival.
Results: Compared with the current screening practices, vaccinating girls
and women ages 12 to 24 years was the most effective strategy, reducing
the number of HPV6/11/16/18-related genital warts, CIN grades 2 and 3,
and cervical cancer cases among women in the next 25 years by 3,049,285,
1,399,935, and 30,021; respectively. The incremental cost-effectiveness
ratio of this strategy when compared with vaccinating girls and women
ages 12 to 19 years was $10,986 per quality-adjusted life-year gained.
Conclusion: Relative to other commonly accepted health-care programs,
vaccinating girls and women ages 12 to 24 years appears cost-effective.
Keywords: cervical intraepithelial neoplasia, condylomata acuminata,
cost-effectiveness analysis, disease transmission, herd immunity, human
papillomavirus, nonlinear dynamics, theoretical models, uterine cervical
neoplasms, vaccines.
Introduction
Genital infections with human papillomavirus (HPV) are among
the most widespread sexually transmitted infections in the United
States and many other countries [1,2]. HPV causes cervical
intraepithelial neoplasia (CIN); cervical, vaginal, vulvar, anal,
and penile cancers; anogenital warts; and recurrent respiratory
papillomatoses (RRP) [3–5]. Despite the substantial reduction in
cervical cancer incidence and mortality in countries with orga-
nized cervical cancer screening programs [6–9], HPV continues
to exert signiﬁcant burden of disease in many populations. For
example, cervical cancer is currently the second most common
malignancy among women, and a leading cause of cancer death
worldwide, with an estimated 493,000 new cases and 274,000
deaths in 2002 [10]. In the United States, about 11,150 cases of
invasive cervical cancer were diagnosed, and approximately
3670 deaths resulted from cervical cancer in 2007 [11].
A number of randomized clinical trials have demonstrated
that a prophylactic HPV vaccine can prevent HPV infection and
disease [12–14]. Following the success of these studies, GARDA-
SIL® (Quadrivalent Human Papillomavirus [Types 6, 11, 16,
and 18] Recombinant Vaccine, Merck & Co., Inc., Whitehouse
Station, NJ) was approved by the US Food and Drug Adminis-
tration. The Centers for Disease Control and Prevention (CDC)’s
Advisory Committee for Immunization Practices recommended
that US girls and women 11 to 26 years old be vaccinated with
GARDASIL (with a provision that females as young as 9 years
old may also be vaccinated) to prevent cervical cancer, precan-
cerous and low-grade lesions, and genital warts caused by HPV
types 6, 11, 16, and 18.
Because GARDASIL is a prophylactic vaccine, maximum ben-
eﬁts will be derived when it is administered to girls before being
exposed to HPV. Because the vaccine targets four HPV types and
persons are not likely to be exposed to all four types, theremay still
be substantial beneﬁts from vaccinating girls and women infected
with fewer than four of the vaccine types. As a person ages, his/her
risk of having been exposed to HPV increases [15–18], and the
incremental beneﬁts may diminish the later a person is vaccinated.
An important policy question that needs to be addressed is which
age groups are appropriate to target for vaccination. Given the
complexity of this policy question, it is useful to employ math-
ematical modeling as a tool for systematically synthesizing exist-
ing data and quantifying the different trade-offs [19].
Recently, a number of studies have been conducted to provide
information on the epidemiologic and economic consequences of
introducing HPV vaccination in the United States [20–28]. The
majority of these studies have projected the beneﬁts and costs of
vaccination over the lifetime of a single cohort. Nevertheless,
because they followed a single cohort, these models could not
account for the indirect beneﬁts and costs of vaccination among
unvaccinated susceptible individuals. In particular, HPV vaccina-
tion will not only protect those with direct vaccine-derived im-
munity to infection but also indirectly protect those who are
susceptible to infection through herd immunity. To account for
these direct and indirect beneﬁts and costs for females and males,
a population dynamic model is necessary. Moreover by tracking
the entire population, a dynamic model can evaluate a broader
range of vaccination strategies (e.g., catch-up vaccination), thus
potentially identifyingmore effective and efﬁcient vaccine policies.
In this article, we used a previously published dynamic model
to assess the HPV 6/11/16/18-related public health impact and
cost-effectiveness of alternative quadrivalent HPV (6/11/16/18)
vaccination strategies [20]. Speciﬁcally, we conducted a decision
analysis to assess the value of varying female HPV vaccination
strategies by speciﬁc age groups for a catch-up vaccination
program.
Materials and Methods
To account for the direct and indirect beneﬁts and costs for
females and males, we constructed a population dynamic model
Address correspondence to: Elamin H. Elbasha, Merck Research Labora-
tories, UG1C-60, PO Box 1000, North Wales, PA 19454-1099, USA.
E-mail: elamin_elbasha@merck.com
10.1111/j.1524-4733.2009.00512.x
Volume 12 • Number 5 • 2009
V A L U E I N H E A LT H
© 2009, Merck & Co., Inc.,Whitehouse Station, NJ, USA 1098-3015/09/697 697–707 697
[20,29–33]. The model was used to evaluate the cost and effec-
tiveness of incrementally expanding the age range of a catch-up
program of vaccinating girls and women with the quadrivalent
HPV (6/11/16/18) vaccine in the United States.
Simulation Model
The simulations were based on an integrated HPV type 6/11/
16/18 disease transmission model and cost-utility analysis [20].
Brieﬂy, the model consists of various components. The demo-
graphic model deﬁnes the demographic characteristics of the
population simulated and describes how individuals enter, age,
and exit the model. It stratiﬁes the population by sex and 17 age
groups (12–14, 15–17, 18–19, 20–24, 25–29, . . . , 80–84, and
over 85). The behavioral model stratiﬁes each age group into
three sexual activity groups (high, medium, low) and describes
the mixing patterns between age and sexual activity groups. The
epidemiologic model simulates heterosexual transmission of
HPV infection and the occurrence of CIN, cervical cancer, and
external genital warts in this age-structured population. In the
cost-utility analysis, we tracked the cost of vaccination, screen-
ing, diagnosis, and treatment of HPV diseases, and quality-
adjusted survival for this population over a planning period of
100 years. The analysis was based on US data and was done from
the US health-care system perspective.
Screening and Vaccination Strategies
We assumed that all vaccination strategies evaluated would be
combined with current cervical cancer screening and HPV
disease treatment practices in the United States. Given that few
children are sexually active before the age of 13 years [34] and
that the CDC [35] has recommended the 11- to 12-year-old
pre-adolescent platform for other childhood vaccinations, we
deﬁned the reference vaccination strategy for this analysis to be
routine HPV vaccination of girls by the age of 12 years. We also
examined HPV vaccination strategies that included a temporary
catch-up program. We expanded the age range of girls and
women covered by the catch-up program to evaluate the incre-
mental costs and beneﬁts of adding catch-up for ages 12 to 14, 15
to 17, 18 to 19, and 20 to 24 years (Table 1).
Parameter Estimates and Sources
A comprehensive search of the literature was conducted to obtain
baseline values for demographic, epidemiologic, screening,
vaccine, and economic parameters of the model [20]. We used
age-stratiﬁed data from the Kaiser Permanente Northwest health
plan, the National Health Interview Survey, and Behavioral Risk
Factor Surveillance System [36–38] to estimate compliance rates
for cervical cytology screening. Estimates of cytology screening
sensitivities and speciﬁcities were based on published studies
[39,40].
The efﬁcacy of the vaccine against incident HPV 6/11 or 16/18
infection was assumed to be 90% [12,14]. We assumed that the
efﬁcacy of the vaccine against HPV 6, 11, 16, and 18-related
disease was 95.2% against any CIN and 98.9% against genital
warts [41,42]. Also, we assumed that the vaccine did not affect the
rate of clearance and infectiousness of breakthrough infections.
The duration of immunity conferred by vaccination is currently
unknown. We assumed that the vaccine conferred lifelong protec-
tion for the base case and examined duration of 10 years in
sensitivity analyses. We assumed that all vaccinated adolescents
would receive a three-dose vaccine before they turn 12 years old,
with vaccine coverage gradually increasing from 0% up to 70%
during the ﬁrst 5 years of the program and remaining at 70%
thereafter. We assumed that vaccine coverage for the temporary
catch-up program, among females not vaccinated by the age of 12
years, would increase linearly from 0% up to 50% during the ﬁrst
5 years and then drop to zero after 5 years.
All model costs were updated to 2005 US dollars using the
medical care component of the Consumer Price Index [43]. The
direct medical costs for screening for and treatment of CIN,
genital warts, and cervical cancer were based on administrative
claims data and other sources [44–46]. We assumed that the cost
of the HPV vaccine for three doses and administration would be
$360 [20]. We did not include productivity costs in the analyses.
To estimate quality adjusted life-years (QALYs), we obtained
health utility values from published sources [47–49]. Finally, all
costs and effects were discounted to present value at an annual
rate of 3%.
Validation Analysis
We established the face validity of the model by consulting with
experts on assumptions regarding the natural history of HPV
infection and disease [50,51]. We also assessed the predictive
validity of the model by comparing model results with epidemio-
logic data reported in the literature for unscreened and screened
populations in the United States. [9,52–55]. We assessed the
convergent validity of the model by comparing its estimates of
the cost-effectiveness of HPV vaccination with those of previ-
ously published studies.
Sensitivity Analysis
One-way sensitivity analyses were performed on vaccine param-
eters (duration, coverage, and cost), quality of life weights, dis-
count rate, analytic horizon, and beneﬁts of preventing HPV
6/11. We also tested the sensitivity of the results to the assump-
tion regarding the durability of the catch-up program by analyz-
ing a scenario where the catch-up vaccination program was
permanent. Additional multivariate sensitivity analyses were per-
formed, including analyses on assumptions regarding sexual
behavior and mixing among age and sexual activity groups. We
also examined the cost-effectiveness of each vaccination strategy
under a pessimistic scenario (duration of protection = 10 years,
vaccine cost per series = $450, health utility reduction from HPV-
related disease 25% lower than base case, degree of protection
Table 1 Cervical cancer screening and HPV vaccination strategies
Description Deﬁnition
I. Screening only Screening of women according to age-speciﬁc rates
II. Routine 12-year-old girls Strategy I + Vaccinate girls before reaching age 12
III. 12-year-old girls + 12–14-year-old female catch-up Strategy II + a temporary catch-up program targeting 12–14-year-old girls
IV. 12-year-old girls + 12–17-year-old female catch-up Strategy II + a temporary catch-up program targeting 12–17-year-old girls
V. 12-year-old girls + 12–19-year-old female catch-up Strategy II + a temporary catch-up program targeting 12–19-year-old girls and women
VI. 12-year-old girls + 12–24-year-old female catch-up Strategy II + a temporary catch-up program targeting 12–24-year-old girls and women
HPV, human papillomavirus.
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against infection = 75%, and degree of protection against HPV-
related disease = 85%) and an optimistic scenario (duration of
protection = lifelong, vaccine cost per series = $270, health
utility reduction from HPV-related disease 25% higher than base
case; degree of protection against infection = 100%, and degree
of protection against HPV-related disease = 100%).
Results
Model Validation
The model predictions generally fell within the range of values
reported in the literature [20]. For example, the predicted age-
speciﬁc HPV 6/11/16/18 attributable CIN 2 and HPV 16/18
attributable CIN 3 incidence curves had a shape and magnitude
at peak similar to data reported in the literature for the United
States [52] (Fig. 1a,b). Figure 1c shows the model’s prediction of
the proportion of adolescent girls and women currently or pre-
viously infected with HPV 16 or 18 by age. This ﬁgure indicates
the level of exposure to HPV 16/18 by age and the extent of
potential beneﬁts of vaccinating at a given age. For example, the
model predicted that 32% of women aged 20 to 24 years have
been exposed to HPV 16/18 and would not derive direct beneﬁts
from vaccination against HPV 16/18 (Additional validation
results are included in a supplementary report that is available to
interested readers upon request).
In an attempt to assess the convergent validity of our model,
we compared our estimates of the cost-effectiveness of HPV
vaccination with those of previously published studies. For
example, in a model assessing the cost-effectiveness of a bivalent
vaccine against HPV 16 and 18 that did not include the herd
immunity effects of vaccination, Sanders and Taira [23] esti-
mated the incremental cost-effectiveness ratio (ICER) of routine
female vaccination at $22,755/QALY (2001$). When the effects
of herd immunity and beneﬁts of prevention of HPV 6/11 were
removed from our model, the ICER of the same strategy was
$21,404/QALY. A recent study employing similar assumptions to
ours, and using a simpliﬁed model, has estimated the ICER of
vaccinating 12-year-old girls routinely with a quadrivalent
vaccine at $5300/QALY [28]. Our estimate was $3200/QALY.
The Baseline Scenario
Vaccinating routinely and adding a catch-up program greatly
reduced the incidence of HPV 16/18-related cervical cancer
(Fig. 2a). Earlier and greater reductions in incidence were
achieved through catch-up vaccination programs with the broad-
est age coverage. As a result, the cumulative incremental impact
(in terms of the number of HPV 16/18 cervical cancer cases
prevented) of the combined routine 12-year and 12- to 24-year-
olds catch-up programs relative to the routine program alone was
signiﬁcant (Fig. 2b). For example, by year 50, more than 30
additional cases could be prevented per 100,000 women in the
population. Table 2 shows the projected additional HPV 6/11/16/
18-related HPV disease cases prevented in the United States in the
next 25 years by different vaccination strategies. For example,
routine vaccination of 12-year-old girls would prevent an esti-
mated 10,051 cases of HPV 16/18-related cervical cancer, and
with a catch-up program that includes ages 12 to 19 years,
additional 13,981 (4498 + 5585 + 3899) cases would be pre-
vented in the next 25 years. If the catch-up program included ages
20 to 24 years, in addition to ages 12 to 19 years, additional 5989
cases of HPV 16/18-related cervical cancer would be prevented in
the next 25 years. The additional cases of HPV 6/11/16/18-related
CIN 2/3 and 6/11-related genital warts among women that would
be prevented in the next 25 years by expanding the age range of the
catch-up vaccination program from 12 to 19 years to 12 to 24
years were 213,710 and 299,498, respectively (Table 2).
Because cervical cancer is a slow-progressing and less common
disease, the effect of vaccination on the reduction in cervical
cancer cases was more gradual and relatively smaller compared
with that for CIN 2/3 or genital warts across all strategies
(Table 2). For example, whereas the total number of cases of HPV
16/18-related cervical cancer prevented using the most effective
strategy of vaccinating girls before the age of 12 years combined
with a 12- to 24-years-of-age catch-up program was 30,021, the
total number of HPV 6/11-related genital warts cases among
women prevented by using the same strategy was 3,049,285.
The reduction in the incidence of genital warts among ado-
lescent boys and men as a result of widespread female vaccina-
tion occurred sooner (Fig. 3). Note that even though boys and
men are not included in any of these vaccination programs, we
would expect a reduction in the incidence of genital warts among
males through herd immunity effects. The reduction is greater,
the broader the age range of the women included in the catch-up
vaccination program.
Ordered from least effective (no vaccination) at the top tomost
effective (routine + 12–24-year-olds catch-up vaccination) at the
bottom, costs, QALYs, and the ICER for each vaccination strategy
are shown in Table 3.We found that strategies that did not include
a catch-up programor included amore restrictive age range for the
catch-up program had higher ICERs thanmore effective strategies
(weakly dominated). For example, we found that routine vacci-
nation of girls by the age of 12 years was less effective and had a
higher ICER than a vaccination strategy that also included a
catch-up program of vaccinating adolescent girls ages 12 to 17
years. Table 3 includes only ICERs of nondominated strategies.
Thus, routinely vaccinating girls before the age of 12 years com-
bined with a 12- to 17-years-of-age catch-up program had an
ICER of $3115/QALY. The ICER of raising the age of women
participating in the catch-up vaccination program to 19 years old
was $3512/QALY. The most effective strategy that included the
full age range (12–24 years) of women included in the catch-up
vaccination program had an ICER of $10,986/QALY.
Another way of presenting the results of the cost-effectiveness
analysis is to plot the efﬁciency frontier that shows the relation-
ship between total cumulative costs (on the x-axis) and total
discounted QALYs (on the y-axis) for ﬁve strategies (Fig. 4).
Moving from left to right, beneﬁts increase as more costly strat-
egies are implemented. Strategies lying on the frontier are efﬁ-
cient, whereas those lying below this frontier are considered
inefﬁcient because they have a higher cost-effectiveness ratio
compared to the next most effective strategy. In this case, routine
vaccination or routine vaccination combined with a 12- to
14-year-olds catch-up program was less efﬁcient compared with
a strategy that expanded the age range of girls included in the
catch-up program to 17 years old. Strategies that include age
groups 12 to 17, 12 to 19, or 12 to 24 years in the catch-up
program all lie on this efﬁciency frontier.
Sensitivity Analyses
The effect of varying duration of vaccine protection on HPV
6/11/16/18-related incidence of CIN 2/3 is shown in Figure 5 for
routine only and routine plus 12- to 24-year-olds catch-up vac-
cination. For both strategies, the impact of vaccination was
smaller in both the short and long term when duration of pro-
tection was shorter. We found that if the duration of protection
was only 10 years, the long-term reduction in the annual number
of HPV 6/11/16/18-related cases of CIN2/3 would be 19%.
Nevertheless, the HPV 6/11/16/18-related incidence of CIN 2/3
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Figure 1 (a) Steady-state human papillomavirus (HPV) 6/11/16/18-related cervical intraepithelial neoplasia (CIN) grade 2 incidence by age in the absence of an HPV
vaccine, and CIN 2 incidence data from the United States. (b) Steady-state HPV 16/18-related CIN grade 3 incidence by age in the absence of an HPV vaccine, and
CIN 2 incidence data from the United States. (c) Steady-state proportion of adolescent girls or women currently or previously infected with HPV 16 or 18 by age
in the absence of an HPV vaccine.
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was 78% lower relative to prevaccination incidence with lifelong
duration of protection. The number of CIN 2/3 cases prevented
by expanding the age range of women included in the catch-up
program was sensitive to our assumption on duration of protec-
tion. For example, by shortening the duration of protection from
lifelong to 10 years, the additional number of CIN 2/3 cases
prevented in the next 25 years by implementing a 12- to 24-year-
olds catch-up program compared with only 12-year-olds routine
vaccination alone fell from 744,247 to 421,585. Changing dura-
tion of vaccine protection also affected the cost-effectiveness
ratios. For example, the ICER of the 12- to 24-year-olds catch-up
vaccination program increased from $10,986/QALY to $18,201/
QALY as a result of changing the duration of protection from
lifelong to 10 years.
The effect of changing the cost of vaccination on the cost-
effectiveness of the various strategies is shown in Table 4. Across
all strategies, the ICER was higher with higher cost of vaccina-
tion. For example, the most effective strategy of vaccinating girls
before the age of 12 years combined with a 12- to 24-years-of-
age catch-up program had an ICER of $18,819/QALY when the
cost of vaccination was $500 for the three-dose series. With a
cost of vaccination of $300, the ICER of this strategy compared
with the next less effective strategy was $7425/QALY.
The public health impact was sensitive to varying vaccination
coverage among adolescent girls. For example, the impact of
vaccination on genital warts among women was lower when the
coverage was 50% compared with 90% (Fig. 6). Although lower
coverage among adolescent girls made vaccinating older girls and
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Figure 2 (a) Incidence of cervical cancer due to
human papillomavirus (HPV) 16/18 infection among
girls and women aged 12 years and over by vacci-
nation strategy. (b) Cumulative incidence (per
100,000 population) of cervical cancer due to HPV
16/18 infection among girls and women aged 12
years and over prevented by adding a 12- to
24-year-old female catch-up program to routine
12-year-old girls vaccination.
Table 2 Additional HPV 6/11/16/18 cases prevented among adolescent girls and women in the United States in the next 25 years by different HPV
vaccination strategies*
Strategy Cervical cancer cases (%) CIN 2/3 cases (%) Genital warts cases (%)
Screening only — — —
Screening + routine 12-year-olds 10,051 (6.9) 655,688 (21.7) 1,783,124 (38.3)
+12–14-year-old female catch-up 4,498 (3.1) 191,341 (6.3) 381,379 (8.2)
+12–17-year-old female catch-up 5,585 (3.8) 209,093 (6.9) 379,359 (8.1)
+12–19-year-old female catch-up 3,899 (2.7) 130,103 (4.3) 205,925 (4.4)
+12–24-year-old female catch-up 5,989 (4.1) 213,710 (7.1) 299,498 (6.4)
Total 30,021 (20.5) 1,399,935 (46.4) 3,049,285 (65.4)
*Cases are incremental to those achieved by the preceding strategy. The percentages represent the proportions of incremental cases prevented by each strategy relative to cases occurring
with screening only. Percentages may not add up to total because of rounding.
CIN 2/3, cervical intraepithelial neoplasia grades 2 and 3; HPV, human papillomavirus.
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women more cost-effective, the impact on ICER was not large.
For example, the ICER of the 12- to 24-year-olds catch-up vac-
cination program decreased from $10,986/QALY to $10,341/
QALY when vaccination coverage among adolescent girls was
changed from 70% to 50%.
With a lower discount rate (1% per year), the discounted
costs and QALYs increased, but the incremental change in
QALYs was relatively larger than that of costs compared with the
base case (Table 4). As a result, expanding the age of vaccination
to 17 years old was weakly dominated by strategies including
ages 12 to 19 and 12 to 24 years. The ICERs of these strategies
also decreased. The ICERs of the catch-up programs for ages 12
to 17 and 12 to 24 years increased with a higher discount rate
(5% per year).
We also assessed the sensitivity of the results to our assump-
tion regarding the durability of the catch-up program. In this
analysis, we assumed that the program would not be discontin-
ued after 5 years and will continue to exist indeﬁnitely. As before,
the program included only those who were never vaccinated
before, and vaccine penetration within this group increased lin-
early from 0 in Year 0 to 50% in Year 5. We assumed the
penetration rates would stay at 50% after Year 5. Because the
catch-up program was permanent, vaccination strategies that
included a catch-up program had a greater and more lasting
impact (Fig. 7). This also changed the results of the cost-
effectiveness analysis. For example, routine vaccination was no
longer weakly dominated (ICER = $3208/QALY), but expanding
the age range of the catch-up program to 12 to 14 years remained
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Figure 3 Incidence of genital warts due to human
papillomavirus 6/11 infection among adolescent
boys and men aged 12 years and over by vaccina-
tion strategy.
Table 3 Cost-effectiveness analysis of alternative HPV vaccination strategies*
Strategy
Discounted total Incremental
Costs, $ QALYs Costs QALYs $/QALY†
Screening only 72,641,950 2,698,713 — — —
Screening + routine 12-year olds 74,111,695 2,699,171 1,469,745 458 Weakly dominated
+12–14-year olds catch-up 74,238,783 2,699,215 127,088 44 Weakly dominated
+12–17-year-olds catch-up 74,351,892 2,699,261 113,108 47 3,115
+12–19-year-olds catch-up 74,451,263 2,699,290 99,371 28 3,512
+12–24-year-olds catch-up 74,924,429 2,699,333 473,167 43 10,986
*Assumes cost of vaccination series is $360 and lifelong duration of protection.
†Compared with the preceding nondominated strategy.A strategy is weakly dominated if there is another more effective strategy that has a lower incremental cost-effectiveness ratio.
HPV, human papillomavirus; QALYs, quality-adjusted life-years.
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Figure 4 Cost-effectiveness of vaccination strate-
gies. Strategies that fall below this frontier are con-
sidered inefﬁcient compared with those lying on
the frontier. For example, routine vaccination by the
age of 12 years has a higher incremental cost-
effectiveness ratio than the more effective strategy
that also includes a 12–17-year-olds catch-up
program. QALY denotes quality-adjusted life-year.
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weakly dominated. With a permanent catch-up program, the
ICERs of expanding the age range of the catch-up program to 15
to 17, 18 to 19, and 20 to 24 years increased to $4,713, $5,235,
and $14,259 per QALY, respectively (Table 5).
We also conducted various sensitivity analyses on assump-
tions regarding sexual behavior and mixing among age and
sexual activity groups. We found that changing the overall mean
number of sex partner (as a measure of sexual activity) changes
the incidence of disease, with higher (lower) sexual activity
leading to higher (lower) incidence of disease. For example,
underestimating the overall number of sex partner change by
20% results in an underestimation of the prevaccination and
long-term postvaccination incidence of cervical cancer by 17%
and 27%, respectively. Also, the level of heterogeneity in sex
partners acquisition rates assumed has a signiﬁcant impact on the
predicted incidence of disease, with more heterogeneity resulting
in higher disease burden. Similarly, assuming a higher transmis-
sion probability per partnership leads to higher estimates of
HPV-related diseases.
Under the pessimistic scenario, the ICER of the routine vac-
cination program jumped to $46,144/QALY, but this and the
strategies of expanding the age range of the catch-up program to
25
0
50
75
100
0 10 20 30 40 50 60 70 80 90 100
Time in Years
In
ci
de
nc
e 
pe
r 
10
0,
00
0 
No Vaccination
12-yo girls (lifelong)
12-yo girls (10-y)
12-yo girls + 12–24 yo female catch up (lifelong)
12-yo girls + 12–24 yo female catch up (10-y)
Figure 5 Sensitivity analysis of the effect of dif-
fering duration of vaccine protection on human
papillomavirus 6/11/16/18-related cervical intraepi-
thelial neoplasia grades 2 or 3 incidence among girls
and women aged 12 years and over by vaccination
strategy.
20
0
40
60
80
100
120
140
160
0 10 20 30 40 50 60 70 80 90 100
Time in Years
In
ci
de
nc
e 
pe
r 1
00
,0
00
 
No Vaccination
12-yo girls (70%)
12-yo girls + 12–24 yo female catch up (70%)
12-yo girls  (90%)
12-yo girls + 12–24 yo female catch up (90%)
12-yo girls (50%)
12-yo girls + 12–24 yo female catch up (50%)
Assumes lifelong duration of vaccine protection 
Figure 6 Sensitivity analysis of the effect of chang-
ing vaccine coverage rate on human papillomavirus
6/11-related genital warts incidence among girls
and women aged 12 years and over by vaccination
strategy.
1
0
2
3
4
5
0 10 20 30 40 50 60 70 80 90 100
Years
In
ci
de
nc
e 
pe
r 1
00
,0
00
 
No Vaccination
12-yo girls
12-yo girls + 12–14 yo female permanent catch up
12-yo girls + 12–17 yo female permanent catch up
12-yo girls + 12–24 yo female temporary catch up
12-yo girls + 12–24 yo female permanent catch up
Assumes lifelong duration of vaccine protection 
Figure 7 Sensitivity analysis of the effect of
making the catch-up vaccination program perma-
nent on human papillomavirus 16/18-related cervi-
cal cancer incidence among girls and women aged
12 years and over by vaccination strategy.
Assessing HPV Vaccination Strategies 703
Ta
bl
e
4
Se
ns
iti
vi
ty
an
al
ys
is
of
ch
an
gi
ng
on
e
in
pu
t
at
a
tim
e
on
in
cr
em
en
ta
lc
os
t-
ef
fe
ct
iv
en
es
s
ra
tio
s
($
/Q
A
LY
)
of
al
te
rn
at
iv
e
H
PV
va
cc
in
at
io
n
st
ra
te
gi
es
*
In
pu
t
ch
an
ge
d/
st
ra
te
gy
R
ou
tin
e
12
-y
ea
r-
ol
ds
+1
2–
14
-y
ea
r-
ol
ds
ca
tc
h-
up
+1
2–
17
-y
ea
r-
ol
ds
ca
tc
h-
up
+1
2–
19
-y
ea
r-
ol
ds
ca
tc
h-
up
+1
2–
24
-y
ea
r-
ol
ds
ca
tc
h-
up
Ba
se
ca
se
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
3,
11
5
3,
51
2
10
,9
86
Va
cc
in
e
co
st
pe
r
se
ri
es
=
$3
00
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
1,
11
4
1,
43
2
7,
42
5
Va
cc
in
e
co
st
pe
r
se
ri
es
=
$5
00
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
7,
73
9
8,
28
4
18
,8
19
D
ur
at
io
n
of
pr
ot
ec
tio
n
=
10
ye
ar
s
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
22
,0
06
Va
cc
in
e
co
ve
ra
ge
=
50
%
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
2,
77
6
3,
28
5
10
,3
41
Va
cc
in
e
co
ve
ra
ge
=
90
%
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
3,
58
6
3,
83
2
11
,8
91
D
eg
re
e
of
pr
ot
ec
tio
n
ag
ai
ns
t
di
se
as
e
=
10
0%
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
2,
88
8
3,
16
4
10
,3
53
D
is
co
un
t
ra
te
=
1%
St
ro
ng
ly
do
m
in
at
ed
St
ro
ng
ly
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
66
4,
29
0
D
is
co
un
t
ra
te
=
5%
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
7,
69
9
7,
82
6
19
,1
13
A
na
ly
tic
ho
ri
zo
n
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
6,
39
7
12
,9
39
N
o
be
ne
ﬁt
s
fr
om
pr
ev
en
tin
g
H
PV
6/
11
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
9,
47
0
19
,3
22
*U
nl
es
s
sp
ec
iﬁ
ed
ot
he
rw
is
e,
a
lif
el
on
g
du
ra
tio
n
of
pr
ot
ec
tio
n
w
as
as
su
m
ed
,c
om
pa
re
d
w
ith
th
e
pr
ec
ed
in
g
no
nd
om
in
at
ed
st
ra
te
gy
.A
st
ra
te
gy
is
w
ea
kl
y
do
m
in
at
ed
if
th
er
e
is
an
ot
he
r
m
or
e
ef
fe
ct
iv
e
st
ra
te
gy
th
at
ha
s
a
lo
w
er
in
cr
em
en
ta
lc
os
t-
ef
fe
ct
iv
en
es
s
ra
tio
.
H
PV
,h
um
an
pa
pi
llo
m
av
ir
us
;Q
A
LY
s,
qu
al
ity
-a
dj
us
te
d
lif
e-
ye
ar
s.
Ta
bl
e
5
Se
ns
iti
vi
ty
an
al
ys
is
of
ch
an
gi
ng
se
ve
ra
li
np
ut
s
at
a
tim
e
on
in
cr
em
en
ta
lc
os
t-
ef
fe
ct
iv
en
es
s
ra
tio
s
($
/Q
A
LY
)
of
al
te
rn
at
iv
e
H
PV
va
cc
in
at
io
n
st
ra
te
gi
es
*
In
pu
t
ch
an
ge
d/
st
ra
te
gy
R
ou
tin
e
12
-y
ea
r-
ol
ds
+1
2–
14
-y
ea
r-
ol
ds
ca
tc
h-
up
+1
2–
17
-y
ea
r-
ol
ds
ca
tc
h-
up
+1
2–
19
-y
ea
r-
ol
ds
ca
tc
h-
up
+1
2–
24
-y
ea
r-
ol
ds
ca
tc
h-
up
Ba
se
ca
se
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
3,
11
5
3,
51
2
10
,9
86
Pe
rm
an
en
t
ca
tc
h-
up
pr
og
ra
m
3,
20
8
W
ea
kl
y
do
m
in
at
ed
4,
71
3
5,
23
5
14
,2
59
O
pt
im
is
tic
sc
en
ar
io
†
C
os
t-
sa
vi
ng
C
os
t-
sa
vi
ng
C
os
t-
sa
vi
ng
C
os
t-
sa
vi
ng
4,
73
6
Pe
ss
im
is
tic
sc
en
ar
io
‡
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
St
ro
ng
ly
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
16
,2
57
N
o
he
rd
im
m
un
ity
ef
fe
ct
s,
an
al
yt
ic
ho
ri
zo
n
=
50
W
ea
kl
y
do
m
in
at
ed
W
ea
kl
y
do
m
in
at
ed
St
ro
ng
ly
do
m
in
at
ed
6,
39
7
12
,9
39
*U
nl
es
s
sp
ec
iﬁ
ed
ot
he
rw
is
e,
a
lif
el
on
g
du
ra
tio
n
of
pr
ot
ec
tio
n
w
as
as
su
m
ed
.Q
A
LY
s,
qu
al
ity
-a
dj
us
te
d
lif
e-
ye
ar
s;
co
m
pa
re
d
w
ith
th
e
pr
ec
ed
in
g
no
nd
om
in
at
ed
st
ra
te
gy
.A
st
ra
te
gy
is
st
ro
ng
ly
do
m
in
at
ed
if
th
er
e
is
an
ot
he
r
m
or
e
ef
fe
ct
iv
e
an
d
le
ss
co
st
ly
st
ra
te
gy
.A
st
ra
te
gy
is
w
ea
kl
y
do
m
in
at
ed
if
th
er
e
is
an
ot
he
r
m
or
e
ef
fe
ct
iv
e
st
ra
te
gy
th
at
ha
s
a
lo
w
er
in
cr
em
en
ta
lc
os
t-
ef
fe
ct
iv
en
es
s
ra
tio
.
† A
ss
um
es
du
ra
tio
n
of
pr
ot
ec
tio
n
=
lif
el
on
g;
va
cc
in
e
co
st
pe
r
se
ri
es
=
$2
70
;h
ea
lth
ut
ili
ty
re
du
ct
io
n
fr
om
H
PV
-r
el
at
ed
di
se
as
e
25
%
hi
gh
er
th
an
ba
se
ca
se
;d
eg
re
e
of
pr
ot
ec
tio
n
ag
ai
ns
t
in
fe
ct
io
n
=
10
0%
;a
nd
de
gr
ee
of
pr
ot
ec
tio
n
ag
ai
ns
t
H
PV
-r
el
at
ed
di
se
as
e
=
10
0%
.
‡ A
ss
um
es
du
ra
tio
n
of
pr
ot
ec
tio
n
=
10
ye
ar
s;
va
cc
in
e
co
st
pe
r
se
ri
es
=
$4
50
;h
ea
lth
ut
ili
ty
re
du
ct
io
n
fr
om
H
PV
-r
el
at
ed
di
se
as
e
25
%
lo
w
er
th
an
ba
se
ca
se
;d
eg
re
e
of
pr
ot
ec
tio
n
ag
ai
ns
t
in
fe
ct
io
n
=
75
%
;a
nd
de
gr
ee
of
pr
ot
ec
tio
n
ag
ai
ns
t
H
PV
-r
el
at
ed
di
se
as
e
=
85
%
.
H
PV
,h
um
an
pa
pi
llo
m
av
ir
us
.
704 Elbasha et al.
12 to 14, 15 to 17, or 18 to 19 years were inefﬁcient. The ICER
of the more efﬁcient strategy of expanding the age range of the
catch-up program to 20 to 24 years increased to $16,257/QALY.
Nevertheless, the routine vaccination program and the strategies
of expanding the age range of the catch-up program to 12 to 14,
15 to 17, or 18 to 19 years are all cost-saving compared with
screening only under the optimistic scenario. The ICER of the
more effective strategy of expanding the age range of the
catch-up program to 20 to 24 years decreased to $4736/QALY.
Discussion
Several studies have assessed the impact of HPV vaccination
[21]. Some of these studies used cohort models to address eco-
nomic issues related to HPV vaccination [22–26], but by not
accounting for herd immunity effects, these models could not
fully assess the impact of HPV vaccination [56–58]. A few
studies used dynamic models to assess the impact of HPV vac-
cination [27,59–62], with only two examining the cost-
effectiveness of vaccination strategies [20,27]. Very few studies
have compared different strategies for vaccinating older adoles-
cent girls or women (Table 6). It should be noted that, whereas
some of the studies listed in Table 6 assessed vaccination in a
broader context of HPV-related infections and diseases (e.g., all
high-risk HPV types), the current study analyzed only diseases
caused by the vaccine types (HPV 6/11/16/18). This study has
demonstrated that a quadrivalent HPV vaccine program that
targets both adolescent girls and women, ages 12 to 24 years,
can have substantial public health beneﬁts and can be cost-
effective ($10,986 /QALY) when compared with other com-
monly accepted medical interventions and vaccines [63].
Although there is greater potential for prior exposure to HPV
with age, there is also anticipated to be substantial public health
beneﬁt in terms of thousands of additional cervical cancers and
hundreds of thousands of additional CIN and genital warts cases
prevented by fully implementing vaccination among 12- to
24-year-old females, compared with more limited strategies
among 12- to 19-, 12- to 17- or 12- to 14-year-olds.
We found that vaccinating 12- to 24-year-old females would
be less cost-effective if the vaccine coverage among adolescent
girls is high, vaccine duration of protection is short-lived, vaccine
degree of protection is low, decrement in quality of life as result
of HPV-related diseases is low, discount rate is high, beneﬁts of
protection against HPV6/11 is low, analytical time horizon is
short, and herd immunity effects resulting from mass vaccination
are small. Nevertheless, this strategy remained cost-effective
under a variety of assumptions, including a pessimistic scenario.
This analysis has several limitations. First, there are limited
data on some important parameters of the model such as the
transmission probability per sexual act and the duration of
natural immunity to HPV infection. Also, data have not been
fully accumulated yet on some vaccine parameters such as dura-
tion of protection, potential cross-protection against nonvaccine
types, and coverage rates across the ages. Furthermore, there are
limited data on utility weights for assessing the health-related
quality of life of HPV disease states. We performed some sensi-
tivity analyses to test the impact of uncertainties due to these
knowledge gaps and found that the conclusions about the cost-
effectiveness of the evaluated vaccination strategies did not
change.
Second, the analysis has been limited to assessing the impact
of the vaccine on cervical diseases and genital warts. By exclud-
ing other diseases that have been linked to HPV 6/11/16/18
infection such as RRP and cancers of the anus, penis, vagina,
vulva, and head and neck, our results underestimated the full
impact of the vaccine. Nor were indirect costs included. Also,
by not including disease due to other HPV types, we did not
capture competing risks of cervical cancer or CIN due to these
other types, which may have overestimated the beneﬁts of HPV
6/11/16/18 vaccination. Nevertheless, the impact of this simpli-
fying assumption is likely to be small for a relatively uncommon
event like type-speciﬁc cervical cancer. Moreover, nearly all pre-
vious models do not capture concurrent CIN disease due to
multiple HPV types. Third, the current version of the model
stratiﬁes the population by speciﬁc broad age groups (12–14,
15–17, 18–19, 20–24, 25–29, . . . , 80–84, and over 85). That
limited our ability to analyze vaccination strategies that are
based only these speciﬁc age groups. For example, we were able
to analyze the impact of a vaccination strategy that includes
ages 12 to 24 years, but we could not evaluate vaccination
Table 6 Summary of previously published models and estimates of the incremental cost-effectiveness ratio (ICER) ($ per QALY or $ per LY gained) by
adding routine HPV vaccination of 12-year-old girls to existing cervical cancer screening in the United States
Study
Key assumptions
ICER*
HPV types Efﬁcacy of vaccine against Vaccine cost
per series, $
Base year
of costTargeted Modeled Infection Disease
Cohort models
Kulasingam and Myers, 2003 [24] H-R H-R 63% 63% 400 2002 $44,889†
Goldie et al., 2004 [26] 16,18 H-R, L-R 70% 90% 393 2002 $28,100
16,18 H-R, L-R 90% 90% 393 2002 $24,300
16,18 H-R, L-R 100% 90% 393 2002 $20,600
Sanders and Taira, 2003 [23] H-R H-R, L-R 75% 75% 300 2001 $12,700
Models with some elements of
transmission dynamics‡
Taira et al., 2004 [27] 16,18 16,18 90% 90% 400 2001 $14,600
Elbasha et al., 2007 [20] 6,11,16,18 6,11,16,18 90% 100% 360 2005 $3,000
Chesson et al., 2008 [28]§ 6,11,16,18 6,11,16,18 100% 100% 360 2005 $5,300
This study 6,11,16,18 6,11,16,18 90% 95% against CIN;
98% against GW
360 2005 $3,200
*With the exception of Kulasingam and Myers, 2003 [24], all studies expressed ICER in terms of $ per QALY.
†$ per life-year gained. Compared with screening women after the age of 24 years biannually with every 3-year screening beginning at the age of 18 years.
‡The assumed rate of vaccine coverage is important when considering transmission dynamics.All transmission dynamics models assumed 70% coverage. For differences between models, see
Dasbach et al. [21].
§Also evaluated the impact of the vaccine on anal, vaginal, vulvar, and orophayngeal cancers, but this was not included in this table.
CIN, cervical intraepithelial neoplasia; GW, genital warts; HPV, human papillomavirus; H-R, high-risk HPV type; L-R, low-risk HPV type; LY, life-year; QALY, quality-adjusted life-year.
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strategies that included the entire age range (9–26 years) for
which data on vaccine safety and efﬁcacy are currently avail-
able. We plan to examine the impact of these strategies using
future versions of the model. We also did not examine the
impact of expanding the age range of the catch-up vaccination
program to include women older than 24 years old nor assessed
the impact of routinely vaccinating girls younger than 9 years
old. As vaccine safety and efﬁcacy data for other age groups
become available, we plan to assess the impact of vaccination
strategies across these age groups.
Finally, because of the complexity of the model, we assessed
the robustness of our conclusions using only deterministic sensi-
tivity analyses. Other researchers, using less complex models,
have employed probabilistic sensitivity analysis (PSA) when
assessing the consequences of decision uncertainty (e.g., [64]).
PSA has the advantage of providing a single global analysis of
uncertainty in input parameters that can potentially improve the
quality of decision-making [65]. Nevertheless, conducting PSA
entails deﬁning a joint probability distribution of model’s inputs
for which sufﬁcient information is often lacking. It is also very
difﬁcult to justify judgmental decisions that are made to obtain
subjective probability distributions for the uncertain model
parameters. More importantly, even if a joint probability distri-
bution of model’s inputs can be characterized, the burden of
computation when incorporating PSA in a complex population
transmission model is so great that makes PSA impractical.
Despite these limitations, the results of this analysis remain
informative and were based on a model that has been extensively
validated against existing epidemiologic data. The model is also
ﬂexible enough to incorporate better data as they become avail-
able. Moreover, all equations and inputs are available for inde-
pendent review and external validation of the model by other
researchers [20].
Our analyses show that in a setting of organized cervical
cancer screening, a prophylactic quadrivalent HPV (16/18/6/11)
vaccine can substantially reduce genital warts, CIN, and cervical
cancer and provide cost-effective survival and quality-of-life
improvements when implemented as a strategy that combines
routine vaccination of 12-year-old adolescent girls with a 12- to
24-year-old female catch-up vaccination program.
Supporting information for this article can be found at: http://
www.ispor.org/publications/value/ViHsupplementary.asp
Source of ﬁnancial support: This study was supported by Merck & Co.,
Inc.
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